<code id='205DD0E6EF'></code><style id='205DD0E6EF'></style>
      • <acronym id='205DD0E6EF'></acronym>
      <center id='205DD0E6EF'><center id='205DD0E6EF'><tfoot id='205DD0E6EF'></tfoot></center><abbr id='205DD0E6EF'><dir id='205DD0E6EF'><tfoot id='205DD0E6EF'></tfoot><noframes id='205DD0E6EF'>
      • <optgroup id='205DD0E6EF'><strike id='205DD0E6EF'><sup id='205DD0E6EF'></sup></strike><code id='205DD0E6EF'></code></optgroup>
        5. <b id='205DD0E6EF'><label id='205DD0E6EF'><select id='205DD0E6EF'><dt id='205DD0E6EF'><span id='205DD0E6EF'></span></dt></select></label></b><u id='205DD0E6EF'></u>
          <i id='205DD0E6EF'><strike id='205DD0E6EF'><tt id='205DD0E6EF'><pre id='205DD0E6EF'></pre></tt></strike></i>
           


   

   

   
   
   
   
   
   
   
   
   
   
   
   
   

   
   
   
   
   
   
   
  
           
  
           
  
           
   
           
    
           
     
           
      
           
       
      
           
      
           
       
           
        
           
         
           
           
          
           
         
           
         
           
           
          
           
         
           
          
        
           
       
           
       
           
        
           
        
           
        
           
        
           
       
           
      
           
       
      
           
      
           
       
           
       
           
       
           
       
           
        
           
        
          
          00:00 
        
           
       
           
       
           
      
           
      
           
        
        
        
       
           
        00:00 
         
        00:00 
        LIVE 
       
           
        
       
           
        
           
        
           
        
           
        
           
       
           
       
           
       
           
        
        
        
        
        
        
        
        
        
      
           
       
    
    
      
           
       
           
      
           
     
           
     
           
       
     
           
     
           
      
           
      
           
      
           
      
           
       
           
      
           
      
           
      
           
       
           
       
          
         buffering 
       
           
      
           
      
           
       
           
        
           
        
          
          Replay 
        
           
       
           
      
           
       
      
           
      
           
       
           
       
           
        
           
        
           
        
           
       
           
      
           
      
           
      
           
      
           
      
           
       
           
      
           
     
           
     
           
      
           
     
           
     
           
      
           
       
           
        
           
       
           
       
           
        
          
          LIVE 
        
           
        00:00 
         /  
        00:00 
       
           
       
           
        
           
        
           
        
           
         
           
         
           
         
           
         
           
         
           
         
           
        
           
        
           
        
           
       
           
       
           
        
           
        
          
          LIVE 
        
           
       
           
       
           
        
           
        
          
          CC 
        
           
       
           
       
           
        
           
       
           
       
           
       
           
        
           
        
           
         
           
        
           
       
           
       
           
        
           
       
           
      
           
      
           
       
           
        
           
        
           
         
           
         
           
         
           
          
           
          
           
          
           
         
           
        
           
       
           
      
           
      
           
       
           
     
       
           
    
       
           
       
    
  
       
           
   
       
           
       
       
           
      
           
      
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       Opacity : 
        
      
           
     
           
     
           
     
           
      
           
  
     
           
    
           
    
           
    
           
     
          
       Share: 
     
           
      
     
           
      
      Copy 
     
           
      
    
           
    
          
      Close 
      
    
           
    
           
      
    
           
    
           
   
           
  
           
  
           
    
    
    
   
           
   
           
 
    
   
           
   
           
   
           
    
           
     
           
      
           
       
           
        
           
          
          
         
          
          explore 

          
          
            
          
          

           
           
        
           
       
           
      
           
     
           
    
           
    
           
     
           
      
           
      
           

                       
          explore  
          
                                   
                 
                                      author：leisure time   
                                        
                                      
                                      -
 
browse：6
                                  
                                    
          
                                    
            
          
 
          Nasdaq
          Mark Lennihan/AP
          The biotech company Acelyrin, which raised more than $500 million in an IPO this year, ran into its first major setback Monday as its investigational anti-inflammatory drug missed the primary goal in a pivotal clinical trial.
          Acelyrin’s medicine, a subcutaneous treatment called izokibep, is meant to clear up lesions for patients with the common skin disease hidradenitis suppurativa, or HS, an inflammatory disorder that leads to abscesses and scars. But after 16 weeks of treatment, patients who received izokibep did not show significant improvements compared to those taking a placebo, failing the study’s primary endpoint.
          advertisement
          Acelyrin’s share price fell more than 60% in after-hours trading Monday.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe													Log In											
           
 
 
          

                              
          
                                 Previous article：

                                
                                          Jerome Adams on the need for new antivirals for Covid
                                
                            
          Next article：  
                                      
                                          Why liver experts renamed NASH to MASH, and NAFLD to MASLD
                                                                    
          

      
           
      
           
        
           
                                               
        
           focus 
           
                   
      
           
  
  
          
    
          
        
          
            
          
                                                     
                
          focus
          
                            
          
        
          
        
    
          

          

    

      
           
     
           


   
    
           
   
           
  
 

  
           
    
           
           
           
            
            Back To Top 
           
           
           
           

            
           
                                                                    
                 
          Wikipedia
           
                                      
            
           
          
           
                                                          
             
          hotspot
           
                             
            
           
            
           

                                                         
             
          leisure time
           
               
              
            
           
            
           
                                                         
             
          knowledge
           
                             
      
           
 
     
           
     
           
      
          
              INAFASSBENDER/AFPviaGettyImagesMorehopefulnewsonthemenopausefront:BayerannouncedonMondayencouragingr
             
           
      
          
        © 2013-2023.Company name All rights reserved.Site Map 
         WSS-More Templates  
             Guangdong ICP6name